Soluble MSLN (SMRP) measured from serum samples has a high specificity but lacks sensitivity for MPM diagnosis, screening, and prognosis; however, it is a useful biomarker to monitor response to therapy because its expression is associated with tumor volume. This evidence concerns the gene MSLN and neoplasm.